Joint contracture
Also known as: Temporomandibular, Temporal, Mandible, Joint
Methodology & AI Transparency ⓘ
Joint contracture Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Cataloged under federal diagnostic code M24.50 in Arthritis & Joints, Joint contracture (also termed Temporomandibular or Temporal) requires synovial fluid crystal/cell in Joint contracture (M24.50: analysis when effused) so specialists can calibrate treatment intensity against hs-CRP & Erythrocyte in Joint contracture (M24.50: Sedimentation Rate) benchmarks.
- 2 Real-world patient consensus: Clinical coding for Joint contracture uses ICD-10 M24.50 across Arthritis & Joints specialty care.
- 3 Typical cash cost range: Primary evaluation for Joint contracture incorporates synovial fluid crystal/cell in Joint contracture (M24.50: analysis when effused) and symptom diary review.
- 4 Top reported side effects / signs: Objective lab/clinical target for Joint contracture: hs-CRP & Erythrocyte in Joint contracture (M24.50: Sedimentation Rate) (hs-CRP < 1.5 mg/L; ESR < 15 mm/hr (M24.50)) and Weight-Bearing Joint Radiograph [Joint contracture M24.50].
Ask our AI Specialists anything about Joint contracture
What Is Joint contracture?
Cataloged under federal diagnostic code M24.50 in Arthritis & Joints, Joint contracture (also termed Temporomandibular or Temporal) requires synovial fluid crystal/cell in Joint contracture (M24.50: analysis when effused) so specialists can calibrate treatment intensity against hs-CRP & Erythrocyte in Joint contracture (M24.50: Sedimentation Rate) benchmarks.
Pathophysiology, Underlying Causes & Clinical Presentation
At the cellular and tissue level in arthritis & joints, Joint contracture (M24.50) involves monosodium urate or in Joint contracture (M24.50: calcium pyrophosphate crystal). progression correlates with shifts in hs-CRP & Erythrocyte in Joint contracture (M24.50: Sedimentation Rate) (hs-CRP < 1.5 mg/L; ESR < 15 mm/hr (M24.50)).
Common Symptoms & Clinical Signs
- • Presentation of Joint contracture (M24.50): localized tendon or in Joint contracture (M24.50: bursa tenderness limiting)
- • Secondary Joint contracture clinical sign: activity-related deep aching in Joint contracture (M24.50: joint pain in)
- • Symptom flares in Joint contracture correlating with hs-CRP & Erythrocyte in Joint contracture (M24.50: Sedimentation Rate) deviation outside hs-CRP < 1.5 mg/L; ESR < 15 mm/hr (M24.50)
- • Functional arthritis & joints impact requiring synovial fluid crystal/cell in Joint contracture (M24.50: analysis when effused) evaluation (M24.50)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Joint contracture Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | M24.50 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Osteoarthritis, Gout & Joint Pain | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: hs-CRP & Erythrocyte in Joint contracture (M24.50: Sedimentation Rate) | hs-CRP < 1.5 mg/L; ESR < 15 mm/hr (M24.50) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Weight-Bearing Joint Radiograph [Joint contracture M24.50] | Preserved joint-space width (M24.50) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Serum Uric Acid in Joint contracture (M24.50: (Gout Target)) | < 6.0 mg/dL (< 5.0 mg/dL with tophi) (M24.50) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Joint contracture
Treatment selection for Joint contracture depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Joint contracture)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Incremental cholesterol reduction with ezetimibe/simvastatin, atorvastatin and: What a 263-Participant Study Found Approximately 45% of. International journal of clinical practice • 2010-07-15 • Randomized Controlled Trial | N = 263 | 93/100 | PMID 20487050 ↗ |
| New Insights on A Phase 3, 28-week, multicentre, randomised, gold-standard blind, compared: What a 498-Participant Study Found LOR was well tolerated despite not meeting the primary endpoint. Clinical and experimental rheumatology • 2025-05-15 • Phase III Randomized Trial | N = 498 | 93/100 | PMID 39808288 ↗ |
| Can This Approach Help? Inside the Latest Research on Effect of ivarmacitinib on swelling and tenderness in small and large joints and Ivarmacitinib 4 mg and 8 mg groups showed greater reductions in bone erosion and synovitis scores under MRI scanning from baseline to W24 versus the placebo group. Naunyn-Schmiedeberg's archives of pharmacology • 2026-05-15 • Phase III Randomized Trial | N = 189 | 88/100 | PMID 41741728 ↗ |
| Can This Approach Help? Inside the Latest Research on Established ASAS definition and preliminary proposed data-driven cut-offs for The purpose of this paper is to evaluate patient characteristics and treatment outcomes in patients with nonradiographic axial spondyloarthritis (nr-axSpA) eligible for a clinical trial based on the 2009 established Assessment... Annals of the rheumatic diseases • 2026-09-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 42350183 ↗ |
| Can This Approach Help? Inside the Latest Research on Response to netakimab in radiographic axial spondyloarthritis patients with Subcutaneous netakimab is effective in patients with r-axSpA irrespective of baseline CRP and inflammation on SIJ MRI. Clinical and experimental rheumatology • 2023-03-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 36062743 ↗ |
Joint contracture Patient Community & “People Like Me” Threads
Filter Joint contracture community threads and patient logs by age, biological sex, dosage, and treatment duration.